H.C. Wainwright lowered the firm’s price target on Newron Pharma (NWPHF) to CHF 44 from CHF 48 and keeps a Buy rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NWPHF:
- FDA halts U.S. recruitment in Newron’s key schizophrenia trial after patient death
- Newron Shareholders Back Board Changes at 2026 General Meeting
- Newron Pharmaceuticals’ Earnings Call Signals Pivotal Year Ahead
- Newron Pharma price target raised to CHF 48 from CHF 43 at H.C. Wainwright
- Newron bolsters finances as Evenamide enters pivotal global Phase III